Its BioHacking

🧬 Welcome to It’s BioHacking. We break down the science behind peptides, longevity, recovery, and human optimization — without the noise. If you care about what actually works, you’re in the right place.

Most people think Tesamorelin = weight loss Wrong. It targets visceral fat (the dangerous kind). This is about body composition + metabolic health. Not just losing weight. #peptides #tesamorelin #Longevity #Biohacking

If you’re taking Retatrutide or considering it be aware of potential side effects. Here’s what we know based off what clinical trials actually show: Most Common Side Effects (GI-related *the big ones*) - Nausea: Up to 38–43% at higher doses (9–12 mg) vs 11% on placebo, roughly 2 out of every 5 people. Most common during dose escalation and usually mild-to-moderate. - Diarrhea: 33–35% at higher doses vs 13% placebo, about 1 in 3 people. - Vomiting: 20–21% at higher doses vs 0–2% placebo, roughly 1 in 5 people. - Constipation: 22–25% at higher doses vs 9% placebo, about 1 in 4–5 people. These GI effects are dose-dependent, happen most during ramp-up, and often ease over time. Slower titration helps. Other Notable Side Effects Include: - Dysesthesia (abnormal skin sensations, tingling, sensitivity, tenderness): 8.8–20.9% at higher doses vs 0.7% placebo, as high as 1 in 5 people on 12 mg. Generally mild and rarely caused discontinuation. - Increased heart rate: Dose-dependent and transient (peaks around 4–7 bpm at higher doses, then often declines). Not a “% of people” issue but a common class effect. - Decreased appetite (beyond the intended effect): 18–19% at high doses. Less Common / Serious Stuff - Overall adverse events: 73–94% of people on retatrutide (vs 70% on placebo) but most are mild GI stuff. - Discontinuation due to side effects: 6–18% depending on dose and trial (vs 0–4% placebo) roughly 1 in 6 to 1 in 16 people stop because of tolerability. - Serious adverse events: 4% (about 1 in 25 people) same rate as placebo. No new red flags in the data so far. - Transient liver enzyme (ALT) rise >3x normal: 1% (1 in 100 people); no hepatotoxicity signals. - Pancreatitis, gallbladder issues, hypersensitivity: Rare and similar to or only slightly higher than other GLP-1 drugs (generally <1–2%, or fewer than 1 in 50–100). No pancreatitis signals above background in most analyses. Retatrutide’s side-effect profile is very similar to other incretin drugs (semaglutide/tirzepatide) but can feel a bit more intense at the highest doses because of the added glucagon effect. Most issues are manageable, happen early, and improve. However, individual responses vary wildly.

@itsloganshippy Do you happen to have website for your products?

I supply 1,000+ clinics pharma-grade #peptides Made in US-based / cGMP facilities. There is no second best. I can show you the entire supply chain. From raws > finished goods.

This is where most people get it wrong. It’s not about doing more— it’s about understanding what actually works. Precision > hype.

Most people think Tesamorelin = weight loss Wrong. It targets visceral fat (the dangerous kind). That’s a different game. #peptides #biohacking

The creator of Claude Code teaches more about vibe-coding in 30 minutes than most tutorials do in hours. Save this — it'll change how you build forever.

Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.

From evidence-based protocols to expert insights and real-world discussions, this is where better questions begin. Explore the science ↓ itsbiohacking.com #Biohacking #Peptides #Longevity

🧬 Welcome to It’s BioHacking. We break down the science behind peptides, longevity, recovery, and human optimization — without the noise. If you care about what actually works, you’re in the right place.